Minireview: Prospect of Doxycycline in Systemic Lupus Erythematosus Treatment

  • Niken Indriyanti Fakultas Farmasi, Mulawarman University, Samarinda, Indonesia
  • Joewono Soeroso Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia
Keywords: doxycycline, non-antibiotic effects, maternity, lupus, drug development

Abstract

Doxycycline has non-antibiotic effects which are necessary for lupus treatment, such as immunosuppressive, anti-inflammatory, and anti-depressive effects. This widely used drug is a promising one to be developed as lupus drug since doxycycline has no data of its microbial resistance and it is safe for maternity. The other benefit is that doxycycline has lower side effects than the current drugs for lupus treatment. It gives excellent chances for women with lupus to be pregnant and have healthy babies. This article contains the compilation data of doxycycline target sites beyond its beneficial activities for lupus and also its limitations. Finally, this data will be a background for doxycycline in lupus drug development.

Downloads

Download data is not yet available.

References

[1] Zampeli E, Klinman DM, Gershwin ME, Moutsopoulos HM, 2017. A comprehensive evaluation for the treatment of lupus nephritis, Journal of Autoimmunity, http://dx.doi.org/10.1016/j.jaut.2016.12.011.
[2] Fiechtner JJ, Montroy T, 2014. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial, Lupus, 23,9,905–12.
[3] Velo-Garca A, Castro SG, Isenberg DA, 2016. The diagnosis and management of the haematologic manifestations of lupus, Journal of Autoimmunity, 74,139–60.
[4] Leite LM, Carvalho AGG, Tavares Ferreira PLF, Pessoa IX, Gonçalves DO, De Araújo Lopes A, et al., 2011. Anti-inflammatory properties of Doxycycline and Minocycline in experimental models: An in vivo and in vitro comparative study, Inflammopharmacology, 19, 2, 99–110.
[5] Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G, 2015. Anti-Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study, Mediators of Inflammation, 2015, http://dx.doi.org/10.1155/2015/329418.
[6] Obradovi H, Krsti J, Kukolj T, Trivanovi D, Dordevi IO, Mojsilovi S, et al. Doxycycline Inhibits IL-17-Stimulated MMP-9 Expression by Downregulating ERK1/2 Activation: Implications in Myogenic Differentiation, Mediators of Inflammation, 2016, 2939658, doi: 10.1155/2016/2939658.
[7] Kovács Z, Kékesi KA, Baracskay P, Juhász G, Czurkó A, 2011. Doxycycline could aggravate the absence-like epileptic seizures of WAG/Rij rats via matrix metalloproteinase inhibition, Neurochemistry Internarional, 59, 5, 563–6.
[8] De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, et al., 2006. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Experimental Eye Research, 83, 3, 526–35.
[9] Bahrehmand F, Vaisi-Raygani A, Kiani A, Rahimi Z, Tavilani H, Ardalan M, et al., 2015. Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress, Lupus, 24, 6, 597–605.
[10] Yu R, Zheng L, Cui Y, Zhang H, Ye H, 2016. Doxycycline exerted neuroprotective activity by enhancing the activation of neuropeptide GPCR PAC1, Neuropharmacology, 103, 1–15.
[11] Ferreira Mello BS, Monte AS, McIntyre RS, Soczynska JK, Custdio CS, Cordeiro RC, et al., 2013. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration, Journal of Psychiatric Research, 47, 10, 1521–9.
[12] Smith K, Leyden JJ, 2005. Safety of doxycycline and minocycline: A systematic review, Clinical Therapy, 27, 9, 1329–42.
[13] Affolter K, Samowitz W, Boynton K, Kelly ED, 2017. Doxycycline Induced Gastrointestinal Injury, Human Pathology, Available from: http://linkinghub.elsevier.com/retrieve/pii/S004681771730062X
[14] Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JHN, 2009. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content, Journal of Vascular Surgery, 49, 3, 741–9.
[15] Rosman Y, Lidar M, Shoenfeld Y, 2014. Antibiotic therapy in autoimmune disorders. Clinical Practice, 11, 1, 91–103.
[16] Smith CJ, Sayles H, Mikuls TR, Michaud K, 2011. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects, Arthritis Research and Therapy, 13, 5, R168.
[17] Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al., 2007. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy and Dermatology, 56, 5, 791–802.
[18] Bastos LFS, Merlo LA, Rocha LTS, Coelho MM, 2007. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models, European Journal of Pharmacology, 576, 1–3, 171–9.
[19] Bensman TJ, Nguyen AN, Rao AP, Beringer PM, 2012. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells, Pulmonary and Pharmacology Therapeutic, 25, 5, 377–82.
[20] Critical PA, Via R, Pathway R-M, Oleifera M, Ameliorates LAM, Arthritis I, et al., 2017. Moringa oleifera lam ameliorates adjuvant induced arthritis via inhibition of inflammatory mediators and down-regulation of mmp3 and mmp-9 proteins, Integrative Medicine Research, 4, 1, 85-94.
[21] Bostanci N, Akgül B, Tsakanika V, Allaker RP, Hughes FJ, McKay IJ, 2011. Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans, Cytokine, 56, 3, 656–61.
[22] Palomino-Morales R, Torres C, Perales S, Linares A, Alejandre MJ, 2016. Inhibition of extracellular matrix production and remodeling by doxycycline in smooth muscle cells, Journal of Pharmacology and Science, 132, 4, 218–23.
[23] Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al., 1997. Matrix Metalloproteinase-8 Is Expressed in Rheumatoid Synovial Fibroblasts and Endothelial Cells: Regulation by TNF and Doxycycline, Journal of Biology and Chemistry, 272, 50, 31504–9.
[24] He Y, Wang X, Bu Y, Song Y, 2016. The impact of genetic variants in matrix metalloproteinase-9 gene on lupus nephritis in Chinese Han population, International Journal of Clinical and Experimental Pathology, 9, 3, 3919–24.
[25] Berzal EU, Boon L, Martens E, Vandooren J, Benedicte C, Opdenakker G, 2017. Matrix metalloproteinase-9 / MMP-9 / gelatinase b in systemic lupus erythematosus (SLE), Lupus Science and Medicine, 4, 1, 118-9.
[26] Aparicio-Soto M, Sánchez-Hidalgo M, Cárdeno A, Rosillo MÁ, Sánchez-Fidalgo S, Utrilla J, et al., 2016. Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-kB and MAPK activation, Journal of Nutrition and Biochemistry, 27, 278–88.
[27] Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, et al., 1998. Inhibition of MMP Synthesis by Doxycycline and Chemically Modified Tetracyclines (CMTs) in Human Endothelial Cells, Advance Dental Research, 12, 1, 114–8.
[28] Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE et al., 2005. Effects of Doxycycline on progression of ostheoarthritis: Results of a randomized, placebo-controlled, double-blind trial, Arthritis and Rheumathology, 52, 7, 2015-25.
[29] Shehwaro N, Langlois AL, Geutin V, Gauthier M, Casenave M, Izzedine H, 2014. Doxycycline or how to create new with the old?, Therapie, 69, 2, 129-41.
[30] Grimstein C, Choi Y-K, Wasserfall CH, Satoh M, Atkinson MA, Brantly ML, et al., 2011. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model, Journal of Translational Medicine, 9, 21.
[31] Castro ML, Franco GCN, Almeida LSB, Anbinder AL, Muller KC, Cortelli SC, 2016. Downregulation of Proteinase-Activated Receptor-2, Interleukin-17, and Other Proinflammatory Genes by Subantimicrobial Doxycycline Dose in a Rat Periodontitis Model, Journal of periodontology, 87, 2, 203-10.
[32] Sawalha AH, Jeffries M, Webb R, Lu Q, Gorelik G, Ray D, et al., 2008. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes, Genes Immunology, 9, 4, 368-78.
[33] Strickland FM, Hewagama A, Wu A, Sawalha AH, Delaney C, Hoeltzel MF et al., 2013. Diet influences expression of autoimmune-associated genes and disease severity by epigenetic mechanisms in a transgenic mouse model of lupus, Arthritis and Rheumathology, 65, 7, 1872-81.
[34] Moy BT, Kapila N, 2016. Probable doxycycline-induced acute pancreatitis. American Journal of Health-System Pharmacy, 73, 5, 286–91.
Published
2019-06-30
How to Cite
Indriyanti, N., & Soeroso, J. (2019). Minireview: Prospect of Doxycycline in Systemic Lupus Erythematosus Treatment. Journal of Tropical Pharmacy and Chemistry, 4(5), 231-237. https://doi.org/10.25026/jtpc.v4i5.173